NeoImuneTech has suspended one clinical trial for the treatment of COVID-19 of NT-I7 (efineptakin alfa), which is being developed as a new immuno-cancer drug.

According to ClinicalTrials.gov operated by NIH in the U.S. on the 12th, it was confirmed that NeoImuneTech withdrew one phase 1 clinical trial related to NT-I7 in the second half of last year.

Earlier, NeoImuneTech was approved by the U.S. Food and Drug Administration (FDA) in June 2020 for two clinical trials related to COVID-19. The withdrawn clinical trial corresponds to a pilot study. Pilot research is a small-scale study conducted to minimize errors before entering large-scale clinical trials of new drugs. Regarding the reason fo